Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO

Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO

BackgroundPatients’ experience of symptoms often goes undetected during consultation in an outpatient clinic, and the use of a patient-reported outcome measure (PRO) in such a setting could be useful to aid treatment decision-making. A new PRO measure, the HM-PRO (Hematological Malignancy Specific P...

Full description

Bibliographic Details
Main Authors: Pushpendra Goswami, Esther N. Oliva, Tatyana Ionova, Roger Else, Jonathan Kell, Adele K. Fielding, Daniel M. Jennings, Marina Karakantza, Saad Al-Ismail, Graham P. Collins, Stewart McConnell, Catherine Langton, Magda J. Al-Obaidi, Metod Oblak, Sam Salek
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Pharmacology
Subjects:
hematological malignancy
Hematology-Specific Patient-Reported Outcome Measure
quality of life
symptoms
reliability
internal-consistency
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2020.571066/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2020.571066/full

Similar Items